Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Operating Income (2016 - 2025)

Karyopharm Therapeutics' Operating Income history spans 14 years, with the latest figure at $31.7 million for Q4 2025.

  • For Q4 2025, Operating Income rose 201.35% year-over-year to $31.7 million; the TTM value through Dec 2025 reached -$41.2 million, up 65.54%, while the annual FY2025 figure was -$41.2 million, 65.54% up from the prior year.
  • Operating Income reached $31.7 million in Q4 2025 per KPTI's latest filing, up from -$15.2 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $47.0 million in Q4 2021 to a low of -$52.4 million in Q1 2021.
  • Average Operating Income over 5 years is -$26.5 million, with a median of -$31.3 million recorded in 2023.
  • Peak YoY movement for Operating Income: surged 226.7% in 2021, then tumbled 172.12% in 2022.
  • A 5-year view of Operating Income shows it stood at $47.0 million in 2021, then crashed by 172.12% to -$33.9 million in 2022, then fell by 11.63% to -$37.8 million in 2023, then grew by 17.26% to -$31.3 million in 2024, then surged by 201.35% to $31.7 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Operating Income are $31.7 million (Q4 2025), -$15.2 million (Q3 2025), and -$24.4 million (Q2 2025).